India Ratings & Research Pvt. Ltd has affirmed the Company s Rating for long term credit facilities at IND A+ , for short term credit facilities at IND A1+ .
Ahmedabad (Gujarat) [India], August 11 (ANI/PNN): Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research and Manufacturing) company with strong capabilities right from process research and development to late-stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, have announced their first quarter (Q1FY23) results. Financial performance Consolidated Q1FY23 review Consolidated Q1FY23 review - Net revenue was Rs 5,406mn for Q1 FY23 as compared to Rs 5,507mn in the corresponding period of the previous year - EBITDA stood at Rs 904 mn for Q1 FY23 as compared to Rs 1,006 mn during the corresponding period of previous year - EBITDA Margin at 16.7 per cent for Q1 FY23 as against 18.3 per cent in Q1 FY22 - Net Profit stood at Rs 40 mn for Q1 FY23 as compared to Rs 160 mn in the corresponding period of the previous year Q1 FY23Result Highlights - Net Revenue at Rs 5,406 mn in Q1 FY23 down by 1.8 per cent YoY mainly on account of low
A Monex subsidiary has rebuffed an Indian drugmaker's £19.4 million ($24 million) lawsuit for canceling currency exchange contracts, saying it was entitled to do so after the pharma firm's offices were raided by the country's authorities.
/PRNewswire/ The vitamin D3 market is fragmented, and the vendors are deploying various organic and inorganic growth strategies to compete in the market..